← FDA DRUG APPROVALS

FDA ANDA · ANDA219442

TOFACITINIB XR

tofacitinib

Sponsor: BIOCON PHARMA

APPLICATION
ANDA219442
TYPE
ANDA
ORIGINAL APPROVAL
2025-11-17
LATEST ACTION
2025-11-17
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription, None (Tentative Approval)

Products

TOFACITINIB CITRATEPrescription
TOFACITINIB CITRATE EQ 11MG BASE · TABLET, EXTENDED RELEASE · ORAL
TOFACITINIB CITRATENone (Tentative Approval)
TOFACITINIB CITRATE EQ 22MG BASE · TABLET, EXTENDED RELEASE · ORAL

Approval history

2025-11-17UNKNOWN · Original · standardTA
2025-11-17UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →